Search

Displaying results 1431 - 1440 of 8517 in total
  1. Drug

    Metaraminol

    go.drugbank.com/drugs/DB00610
    Approved

    It has been used primarily as a vasoconstrictor in the treatment of hypotension.

  2. Drug

    Empagliflozin

    go.drugbank.com/drugs/DB09038
    ApprovedInvestigational

    [L13688] The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for … [A203501] As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold).

  3. Drug

    Sinapultide

    go.drugbank.com/drugs/DB11332
    ApprovedWithdrawn

    This has led to the development of newer synthetic surfactants such as lucinactant (Surfaxin), which contains sinapultide. … Sinapultide (also known as KL4 peptide) is a synthetic protein used to mimic human lung surfactant protein B.[L2502] This protein has a weight of 2469.40.

  4. Drug

    Haloprogin

    go.drugbank.com/drugs/DB00793
    ApprovedWithdrawn

    Haloprogin is used as a topical ointment or cream in the treatment of Tinea infections. … Haloprogin is no longer available in the United States and has been discontinued.

  5. Drug

    Ondansetron

    go.drugbank.com/drugs/DB00904
    ApprovedInvestigationalWithdrawn

    Commonly formulated as oral tablets, orally disintegrating tablets (ODT), and injections, and available as generic products as well, ondansetron continues to see contemporary innovations in its formulation … Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy.

  6. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    [A3197] Ganaxolone belongs to a class of compounds referred to as neurosteroids. … [L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636]

  7. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    [A258453] Trofinetide is marketed as DAYBUE and DAYBUE STIX in the United States, as DAYBUE in Canada, and as DAYBU in the European Union. … Trofinetide is a novel synthetic analog of [glypromate], also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor

  8. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    many as 40% of patients will experience relapsed or refractory disease. … It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.

  9. Drug

    Varenicline

    go.drugbank.com/drugs/DB01273
    ApprovedInvestigational

    A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S. … Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may

  10. Drug

    Leuprolide

    go.drugbank.com/drugs/DB00007
    ApprovedInvestigational

    [A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron™ by Abbvie Endocrine Inc. … [A203222] As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels.